Cypherpunk Technologies (NASDAQ:CYPH) Shares Pass Below Fifty Day Moving Average – What’s Next?

Cypherpunk Technologies (NASDAQ:CYPH) crossed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $0.87 and traded as low as $0.6218. Cypherpunk Technologies shares last traded at $0.7160, with a volume of 4,142,837 shares.

Wall Street Analyst Weigh In

Several analysts have commented on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Cypherpunk Technologies in a report on Thursday, January 22nd. Wall Street Zen raised shares of Cypherpunk Technologies from a “sell” rating to a “hold” rating in a research note on Tuesday, November 25th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Cypherpunk Technologies Price Performance

The stock has a market capitalization of $21.28 million, a price-to-earnings ratio of -0.42 and a beta of -0.16. The stock has a 50 day moving average price of $0.84 and a 200-day moving average price of $0.84.

Institutional Investors Weigh In On Cypherpunk Technologies

Hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new position in Cypherpunk Technologies during the fourth quarter worth about $37,000. LPL Financial LLC acquired a new position in shares of Cypherpunk Technologies during the 4th quarter worth approximately $38,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at approximately $44,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at approximately $56,000. Finally, HighTower Advisors LLC purchased a new position in Cypherpunk Technologies during the fourth quarter worth approximately $59,000. 30.46% of the stock is currently owned by institutional investors and hedge funds.

About Cypherpunk Technologies

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.